| 1. Comprehensive quantitative analysis of plasma protein constituents among individuals later diagnosed with cancer who were part of large study population cohorts for identifying proteins predictive of the onset or risk for major common cancers. Aliquots are distributed to participating investigator for analyses that encompass protein modifications and autoantibody responses. |
| 2. Comprehensive quantitative analysis of protein constituents in plasmas collected at diagnosis and postdiagnosis to identify signatures informative about the tissue of origin, molecular subtypes, prognosis, prediction of treatment response, and tumor recurrence. |
| 3. Development of affinity capture agents for plasma proteins to be used in assays that have platforms with the prerequisite analytical sensitivity and specificity. |
| 4. Development of proteotypic peptides applicable to proteins with cleavages and other modifications associated with cancer. |
| 5. Development of a publicly available cancer plasma proteome database with links to experimental data. |
